Implications of the CANVAS Study in Reducing Cardiovascular Outcomes

Paramasivan, Ameena Madan; Purushothaman, Archana; Desouza, Cyrus

doi:10.1007/s11892-018-1106-1

Cited by 1 publication

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This included a significant reduction in CV death and hospitalization for HF in patients treated with empagliflozin. Subsequent large trials with other SGLT2-Is, such as canagliflozin (CANVAS (Canagliflozin Cardiovascular Assessment Study) [ 33 ] and CREDENCE (Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy) trials [ 34 ]) and dapagliflozin (DECLARE-TIMI 58 (Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes) trial [ 35 ]), confirmed these observations in a broader population of primary and secondary prevention patients [ 36 , 37 ]. O’Hara et al, in a recent review, showed that the administration of dapaglifozin in non-diabetic patients may prevent the onset of overt diabetes mellitus [ 38 ].…”

Section: Introductionmentioning

confidence: 99%

Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors

et al. 2022

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia and associated with an increased risk of morbidity and mortality, primarily from cardiovascular and renal diseases. Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) are novel drugs for the treatment of type 2 DM and heart failure (HF). SGLT2-Is mediate protective effects on both the renal and cardiovascular systems. This review addresses the current knowledge on the biomolecular mechanisms of the cardiorenal protective effects of SGLT2-Is, which appear to act mainly through non-glucose-mediated pathways. Cardiorenal protection mechanisms lead to reduced chronic renal disease progression and improved myocardial and coronary endothelial function. Concomitantly, it is possible to observe reflected changes in biomarkers linked with diabetic kidney disease and HF.

show abstract